NO20092099L - DMAE as sole agent for the treatment of mild cognitive impairment - Google Patents

DMAE as sole agent for the treatment of mild cognitive impairment

Info

Publication number
NO20092099L
NO20092099L NO20092099A NO20092099A NO20092099L NO 20092099 L NO20092099 L NO 20092099L NO 20092099 A NO20092099 A NO 20092099A NO 20092099 A NO20092099 A NO 20092099A NO 20092099 L NO20092099 L NO 20092099L
Authority
NO
Norway
Prior art keywords
dmae
treatment
cognitive impairment
mild cognitive
sole agent
Prior art date
Application number
NO20092099A
Other languages
English (en)
Inventor
Pierre Fabre
Christophe Przybylski
Bruno Dubois
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of NO20092099L publication Critical patent/NO20092099L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse vedrører anvendelsen av dimetylaminetanol (DMAE), som eneste aktive ingrediens, i fri form eller i formen av salter eller estere og også av hydrater og solvater derav, i fremstillingen av et medikament til anvendelse i behandlingen av ikke-dement, mild, kognitiv forstyrrelse, som er karakterisert ved et amnesisyndrom av hippokampustype.
NO20092099A 2006-10-31 2009-05-28 DMAE as sole agent for the treatment of mild cognitive impairment NO20092099L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0609548A FR2907679B1 (fr) 2006-10-31 2006-10-31 Utilisation de dmae pour le traitement de deficit cognitif leger
PCT/EP2007/061737 WO2008053011A1 (fr) 2006-10-31 2007-10-31 Le dmae en tant qu'agent unique pour le traitement de deficit cognitif leger

Publications (1)

Publication Number Publication Date
NO20092099L true NO20092099L (no) 2009-07-17

Family

ID=38050144

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092099A NO20092099L (no) 2006-10-31 2009-05-28 DMAE as sole agent for the treatment of mild cognitive impairment

Country Status (18)

Country Link
US (1) US8207218B2 (no)
EP (1) EP2083814B1 (no)
JP (1) JP2010508253A (no)
KR (1) KR20090082428A (no)
CN (1) CN101528220A (no)
AR (1) AR063764A1 (no)
AU (1) AU2007316137A1 (no)
BR (1) BRPI0718263A2 (no)
CA (1) CA2667983A1 (no)
FR (1) FR2907679B1 (no)
IL (1) IL198463A0 (no)
MA (1) MA30925B1 (no)
MX (1) MX2009004682A (no)
NO (1) NO20092099L (no)
RU (1) RU2009120137A (no)
TN (1) TN2009000159A1 (no)
WO (1) WO2008053011A1 (no)
ZA (1) ZA200903626B (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150157046A1 (en) * 2013-12-10 2015-06-11 Lifewave, Inc. Nutritional product composition for the mind

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003981A2 (en) * 2001-07-05 2003-01-16 Vital Basics, Inc. Compositions for improving mental performance
US20060211721A1 (en) * 2005-03-21 2006-09-21 Roberts Alan R Nutraceutical formulation of a cognitive enhancement system

Also Published As

Publication number Publication date
CN101528220A (zh) 2009-09-09
JP2010508253A (ja) 2010-03-18
US8207218B2 (en) 2012-06-26
AU2007316137A1 (en) 2008-05-08
MX2009004682A (es) 2009-09-28
EP2083814B1 (fr) 2013-03-20
RU2009120137A (ru) 2010-12-10
WO2008053011A1 (fr) 2008-05-08
KR20090082428A (ko) 2009-07-30
US20090298908A1 (en) 2009-12-03
MA30925B1 (fr) 2009-11-02
ZA200903626B (en) 2010-07-28
CA2667983A1 (fr) 2008-05-08
FR2907679A1 (fr) 2008-05-02
BRPI0718263A2 (pt) 2014-01-07
EP2083814A1 (fr) 2009-08-05
IL198463A0 (en) 2010-02-17
TN2009000159A1 (fr) 2010-10-18
AR063764A1 (es) 2009-02-18
FR2907679B1 (fr) 2009-10-30

Similar Documents

Publication Publication Date Title
BRPI0507198A (pt) derivados de bisariluréia
DK1807072T3 (da) Cycloalkyllactamderivater som inhibitorer af 11-beta-hydroxysteroid-dehydrogenase 1
NO20083057L (no) Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer
SG171649A1 (en) Dpp iv inhibitor formulations
BRPI0908421C1 (pt) solução estável de um composto farmacêutico
MY149622A (en) Pyrazoles as 11-beta-hsd-1
CL2008003003A1 (es) Mezcla binaria que comprende 2-amino-2-[2-(4-octil-fenil)etil]propano-1,3-diol (fty720) y un excipiente seleccionado de lactosa, hpmc, hpc, crospovidona, croscarmelosa de sodio, almidon y dioxido de silicio coloidal, y su uso para el tratamiento de enfermedades autoinmunes, entre otras.
NO20065880L (no) 3-Amino-l-arylpropylindoler som monoamin-gjenopptagelsesinhibitor
DK2029529T3 (da) Substitueret pyrrolidinone som inhibitor af 11-beta-hydroxysteroiddehydrogenase 1
PT2222669E (pt) Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p)
WO2007144327A3 (en) Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands
UY29079A1 (es) Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
CL2008001465A1 (es) Compuestos derivados de [2,1,3]benzoxadiazol-5-carboxamidas, moduladores de los receptores ampa; composiciones farmacéuticas; y su uso en el tratamiento de afecciones hipoglutamatérgicas, trastornos cognitivos, enfermedad de parkinson, adhd, síndrome de rett, depresión respiratoria, síndrome x frágil y enfermedad de alzheimer.
NO20092535L (no) Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol
MY174002A (en) Combination theraphy for the treatment of diabetes
EA201070477A1 (ru) Транс-кломифен для лечения метаболического синдрома
WO2008063933A3 (en) Pak modulators
NO20075920L (no) Assosiasjon mellom ferroquin og et artemisininderivat for behandling av malaria
NO20083836L (no) N-hydroksyakrylamidforbindelser
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
NI200900052A (es) Heterocíclicos derivados de los inhibidores de metaloproteasa
NO20080936L (no) Transdermale medikamentleveringsinnretninger inneholdende O-desmetylvenlafaksin (ODV) eller salter derav
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application